Immune checkpoint blockade in advanced hepatocellular carcinoma: an update and critical review of ongoing clinical trials

Por Harding, James J
Publicado no Future Oncol (2018)

Understanding and quantifying the immune microenvironment in hepatocellular carcinoma

Por Osorio, Juan C., Harding, James J.
Publicado no Transl Gastroenterol Hepatol (2018)

Predicting responsiveness to sorafenib: can the determination of FGF3/FGF4 amplifications enrich for clinical benefit?

Por Harding, James J., Abou-Alfa, Ghassan K.
Publicado em 2014

Cutis Verticis Gyrata in Association With Vemurafenib and Whole-Brain Radiotherapy

Por Harding, James J., Barker, Christopher A., Carvajal, Richard D., Wolchok, Jedd D., Chapman, Paul B., Lacouture, Mario E.
Publicado no J Clin Oncol (2014)

Adjuvant medications that improve survival after locoregional therapy

Por Boas, F. Edward, Ziv, Etay, Yarmohammadi, Hooman, Brown, Karen T., Erinjeri, Joseph P., Sofocleous, Constantinos T., Harding, James J., Solomon, Stephen B.
Publicado no J Vasc Interv Radiol (2017)

Aspirin Is Associated With Improved Liver Function After Embolization of Hepatocellular Carcinoma

Por Boas, F. Edward, Brown, Karen T., Ziv, Etay, Yarmohammadi, Hooman, Sofocleous, Constantinos T., Erinjeri, Joseph P., Harding, James J., Solomon, Stephen B.
Publicado no AJR Am J Roentgenol (2019)

Pharmacokinetic Assessment of (18)F-(2S,4R)-4-Fluoroglutamine in Patients with Cancer

Por Grkovski, Milan, Goel, Reema, Krebs, Simone, Staton, Kevin D., Harding, James J., Mellinghoff, Ingo K., Humm, John L., Dunphy, Mark P.S.
Publicado no J Nucl Med (2020)

Human cytomegalovirus decreases constitutive transcription of MHC class II genes in mature Langerhans cells by reducing CIITA transcript levels

Por Lee, Andrew W., Wang, Nan, Hornell, Tara M.C., Harding, James J., Deshpande, Chetan, Hertel, Laura, Lacaille, Vashti, Pashine, Achal, Macaubas, Claudia, Mocarski, Edward S., Mellins, Elizabeth D.
Publicado em 2011

Acute myeloid leukemia masquerading as hepatocellular carcinoma

Por Abu-Zeinah, Ghaith F., Weisman, Paul, Ganesh, Karuna, Katz, Seth S., Dogan, Ahmet, Abou-Alfa, Ghassan K., Stein, Eytan M., Jarnagin, William, Mauro, Michael J., Harding, James J.
Publicado no J Gastrointest Oncol (2016)

Characterization and phase I study of CLR457, an orally bioavailable pan-class I PI3-kinase inhibitor

Por Harding, James J., Bauer, Todd M., Tan, Daniel S. W., Bedard, Philippe L., Rodon, Jordi, Doi, Toshihiko, Schnell, Christian, Iyer, Varsha, Baffert, Fabienne, Radhakrishnan, Rajkumar, Fabre, Claire, Juric, Dejan
Publicado no Invest New Drugs (2018)

Nanoliposomal irinotecan with fluorouracil for the treatment of advanced pancreatic cancer, a single institution experience

Por Glassman, Danielle C., Palmaira, Randze L., Covington, Christina M., Desai, Avni M., Ku, Geoffrey Y., Li, Jia, Harding, James J., Varghese, Anna M., O’Reilly, Eileen M., Yu, Kenneth H.
Publicado no BMC Cancer (2018)

Four-month course of adjuvant dabrafenib in patients with surgically resected stage IIIC melanoma characterized by a BRAFV600E/K mutation

Por Momtaz, Parisa, Harding, James J., Ariyan, Charlotte, Coit, Daniel G., Merghoub, Taha, Gasmi, Billel, You, Daoqi, Viale, Agnes, Panageas, Katherine S., Samoila, Aliaksandra, Postow, Michael A., Wolchok, Jedd D., Chapman, Paul B.
Publicado no Oncotarget (2017)

Progression of RAS-Mutant Leukemia during RAF Inhibitor Treatment

Por Callahan, Margaret K., Rampal, Raajit, Harding, James J., Klimek, Virginia M., Chung, Young Rock, Merghoub, Taha, Wolchok, Jedd D., Solit, David B., Rosen, Neal, Abdel-Wahab, Omar, Levine, Ross L., Chapman, Paul B.
Publicado em 2012

Phase II trial of sorafenib and doxorubicin in patients with advanced hepatocellular carcinoma after disease progression on sorafenib

Por El Dika, Imane, Capanu, Marinela, Chou, Joanne F., Harding, James J., Ly, Michele, Hrabovsky, Anna D., Do, Richard K.G., Shia, Jinru, Millang, Brittanie, Ma, Jennifer, O’Reilly, Eileen M., Abou‐Alfa, Ghassan K.
Publicado no Cancer Med (2020)

A phase 1 study of ADI-PEG 20 and modified FOLFOX6 in patients with advanced hepatocellular carcinoma and other gastrointestinal malignancies

Por Harding, James J., Do, Richard K., Dika, Imane El, Hollywood, Ellen, Uhlitskykh, Khrystyna, Valentino, Emily, Wan, Peter, Hamilton, Casey, Feng, Xiaoxing, Johnston, Amanda, Bomalaski, John, Li, Chien-Feng, O’Reilly, Eileen M., Abou-Alfa, Ghassan K.
Publicado no Cancer Chemother Pharmacol (2018)

PTEN Loss-of-Function Alterations Are Associated With Intrinsic Resistance to BRAF Inhibitors in Metastatic Melanoma

Por Catalanotti, Federica, Cheng, Donavan T., Shoushtari, Alexander N., Johnson, Douglas B., Panageas, Katherine S., Momtaz, Parisa, Higham, Catherine, Won, Helen H., Harding, James J., Merghoub, Taha, Rosen, Neal, Sosman, Jeffrey A., Berger, Michael F., Chapman, Paul B., Solit, David B.
Publicado no JCO Precis Oncol (2017)

A Retrospective Evaluation of Vemurafenib as Treatment for BRAF-Mutant Melanoma Brain Metastases

Por Harding, James J., Catalanotti, Federica, Munhoz, Rodrigo R., Cheng, Donavan T., Yaqubie, Amin, Kelly, Nicole, McDermott, Gregory C., Kersellius, Romona, Merghoub, Taha, Lacouture, Mario E., Carvajal, Richard D., Panageas, Katherine S., Berger, Michael F., Rosen, Neal, Solit, David B., Chapman, Paul B.
Publicado no Oncologist (2015)

Efficacy of Intermittent Combined RAF and MEK Inhibition in a Patient with Concurrent BRAF- and NRAS-Mutant Malignancies

Por Abdel-Wahab, Omar, Klimek, Virginia M., Gaskell, Alisa A., Viale, Agnes, Cheng, Donavan, Kim, Eunhee, Rampal, Raajit, Bluth, Mark, Harding, James J., Callahan, Margaret K., Merghoub, Taha, Berger, Michael F., Solit, David B., Rosen, Neal, Levine, Ross L., Chapman, Paul B.
Publicado no Cancer Discov (2014)

Evolution of Surgical Management of Gallbladder Carcinoma and Impact on Outcome: Results from two decades at a single-institution

Por Creasy, John M., Goldman, Debra A., Gonen, Mithat, Dudeja, Vikas, O’Reilly, Eileen M., Abou-Alfa, Ghassan K., Cercek, Andrea, Harding, James J., Balachandran, Vinod P., Drebin, Jeffrey A., Allen, Peter J., Kingham, T. Peter, D’Angelica, Michael I., Jarnagin, William R.
Publicado no HPB (Oxford) (2019)

NRF2 Dysregulation in Hepatocellular Carcinoma and Ischemia: A Cohort Study and Laboratory Investigation

Por Ziv, Etay, Zhang, Yiru, Kelly, Luke, Nikolovski, Ines, Boas, F. Edward, Erinjeri, Joseph P., Cai, Liqun, Petre, Elena N., Brody, Lynn A., Covey, Anne M., Getrajdman, George, Harding, James J., Sofocleous, Constantinos, Abou-Alfa, Ghassan K., Solomon, Stephen B., Brown, Karen T., Yarmohammadi, Hooman
Publicado no Radiology (2020)